!0 - - PDF document

• !"#$%&'(!")**

'+)!+)+(!))+,+' )'(!+!

• !)+*.-'*+!!++()'(-

(!"+++(*(+)*!!*.(+

• ".

++ /

• 0(12345
• !"#$%&'()*(+

6-*!-78+6 !!+!(!+(--

9 ( *!- + $& *- +(--"! !-78+(* !!(.*$6& 7"+*:-);51<"* *()4=1*>!+! *9*-* ' + *, '!* ?+. " * ()( +(!245?!! 44@ ",#) *- 9 (** ) !

• 78667(!6$'!(!A@&

+* : ) ;51< $A;& + )+ $-(4&**(" 4=1* +* ) *!-+ +*! * $21< A2& *!-+ !(.* ) $421< A4& ! $& " 21< ( !!436"B!2+ 2)*)* 6( +(+ */+!

• -! - "!!?! 0 +(7!

)+ 6$AC&9*-*((-(+ *-+* ?+.!! +(+*! )--( 245"!?!( 44@**! "!!*"!"!! +(+-)+(-?D +(9!+!+!-*!" )+( (!? +( ?! *( ("!!)( ,""#)-"+(- 9E'!!'!* *! ). -*$( &*?+.F'

• +-)*))+(!??!! $-(2&
• *)"!'"-786

7(!*-( 8!'! *!!))+"* * ")>-(/( --+)G43('!( +*! ! ,( (*?)?? ! >!'9*('!(-'"- )*(! ! - '!* ! 4? 2?! 6

• +.H
• %
• H
• !

+-H '(.)..

• /"01

+$B7272345& G4C4 12I>.-$B7C7234B& G@45 12I>."$17;472345& G45@ 6.$66& G4C ($66& ==25

• "0##"#1$&
• ,23 ))

6--+7 /+!- ! $242&C1;?=C5@ ,J!!"!+*

• !+.:

!+.:

• $+
• 4K

2K ;K =K

• 7
• 4&(5
• ?42;

?35= ?352 ?35; ?;2@

• 4&(6
• ?2B1

?4CB ?32C ?3@3 ?===

• 4&(7
• ?1BC

?=4; ?2B3 42@ ?431=

• 4&(8
• ?2C=4
• !

• 0(12345
• !"#*
• +'(+
• 2)@

!0 ,J!!"!+*

• 4"0!(1,"0#"9:;""/"<<"#!,#"
• "#$$%&'!

4"0!=1,"0#"9:;,/ "#"###

• "#$$%&'!
• Number of AML patients treated

Evaluable for response 10 8 Overall response 3 (37.5%) Morphologic complete remission Morphologic leukemia free state Treatment failure Stable disease 2 (25%) 1 (12.5%) 3 (37.5%) 2 (25%) Not evaluable for response (per protocol) 2 Median duration of treatment (months) 14.5

UPN Age (yrs) Cohort* Previous Therapy DoT (months) AML Status at Study Entry IWG Response (D0R) – weeks) 101-033 61 140 bid

• 1. Induction
• 2. Investigational

4.0 Refractory NE 101-002 70 140 bid Growth Factors 29.6 Secondary MoCR (25.3) 102-001 76 140 bid Growth Factors 4.0 MDS/AML NE 102-003 78 140 bid Growth Factors 55.1 MDS/AML MoCR (43) 101-005 73 280 bid 1. Induction 2. DEC x 5 4.0 1st Relapse TF/I 102-009 71 560/280 1. Induction x 2 2. AZA x 25 12.9 Relapsed TF/R 102-007 80 560/280 AZA x 5 32.0 Secondary TF/R 101-008 57 560/280 Induction 8.1 Refractory MLFS (4.1) 101-009 60 560/280 Induction 24.4 Relapsed SD 101-007 77 560/280 1. Induction 2. DEC x 5 16.0 Relapsed SD

MDS/AML – 20 to <30% blasts NE – patients off study prior to 12 weeks of combination MoCR – morphologic complete remission TF/I – treatment failure/indeterminate TF/R – treatment failure/resistant MLFS – morphologic leukemia-free state SD – stable disease

*Oral rigosertib dose

• 0(12345
• !"#*
• +'(+
• ;)@

!0 ,J!!"!+*

• /!

/""

• ""0
• !! (( -)!

)*(!8++*)?! * =:>(5

• !! $&*

(!*.,(*) =(5

• !! +*!$&

+(* ((?

• !! $&?!

(! ((?

• !! !)*(!8+

+*( )?!* =.(?

• 6 ! !+ *

$6&?-.

• 0(12345
• !"#*
• +'(+
• =)@

!0 ,J!!"!+*

• ,"", #!/ <",! !,/ @ " % # ,!)

F'( -)---( " (+*)*+'! ))!+!+! ( $6&+. ) +! ( +! +(!!! ) )'!)( +)! !-'-! +!+!! '+ 9E )! -' (! ) ! +!+! ( +(! ' *!! -' *+ !'!( " !#&0//!09"0,"",,#!##<!,//3 "# ,!,0 #0"/#!<<"","",,"/"/ < #0!")!(-!"*( (*-"."))"+(-- ' ' F' ++8 !! L((--!M !! - +!+! . ) -- +*(--*'*!+(!- '!*!)* /!9/ ""/#,#)!(-9E +(!(++!! !- -' : !-'+!+!(+*)*+()((!N *! ,+" )(+"(!'

• (! -+')(+"*.!+(!
• )+! !",+(+)+(+!!('!

++()+-(-+-)*-* +)+*!+-+-)!:! *(* '( (!. !" :+ +(! ! -'! ))+9!'!( //"",<""0#!,//",!# ,/,!)!(-+* OG2166+)*!23459*!.! "(!* )+!(+--)") "+*!-+!+! '!* !! : )( '! ! ! (! )(( ! : +!! )* # F + -)+! (+ +' '! (+ '(+:+N+* *-("P( ! + (+ + '!( ) :- !+(!!(

0(12345 !"#* 4@=2 +'(+

• 1)@

!0 ,J!!"!+*

• !

"

• #
• !"#
• #
• "$
• %$
• &'
• #$%&
• $#

() () () () () () () () () ()

• %**+,
• ()

()

• ()

() () () () () ()

• .
• !%$

()

• *$.

() () () () () () () () () ()

• $.
• '(

() () () () () () () () () ()

• !/%-

() () () () () () () () () ()

• 0*$*'

$$'% () () () () () () () () () ()

• 1%

(23) (23) (23) (23) (23) (23) (23) (23) (23) (23) 23 23 23 #%%%

• )$*#+,-#."

* 4 4 4 4 4 56 4 4 4 4 4 4 4 4 4 4 4 4 4 #"50 4 4 4 4 4 4 4 4 4 4 4 4 4 !-$() 4 4 4 4 4 4 4 4 4 4 4 4 4

• $

4 4 4 4 4 4 4 4 4 4 4 4 4 /#%01*#+22, / 4 4 4 4 4 4 4 4 4 4 4 4 4 "50 4 4 4 4 4 4 4 4 4 4 4 4 4 56 4 4 4 4 4 4 4 4 4 4 4 4 4 &5# 4 4 4 4 !-$(7) 4 4 4 4 4 4 4 4 4 4 4 4 4 8.-$ 4 4 4 4 4 4 4 4 4 4 4 4 4

• $

4 4 4 4 4 4 4 4 4 4 4 4 4 98# 4 4 4 4 4 4 4 4 4 4 4 4 4

2#34567689 !8: !"#$

• :

8

• 9

;

• 0(12345
• !"#*
• +'(+
• B)@

!0 ,J!!"!+*

H

4

! !)+) +)'":--+* +*+(++(! !'"+++*+' ! ) +)++**'"+ () **)**)*! (!*+(*

• ()-(-(! (!P()*--)-+-$-/( 7/( ?'"-!

"-7!!&-!))*Q"-+-!(-)*E-)/( 7'"-!"-7!!*+!! + /( !!!+'! *-*+((-*!'-! +(')+. ! Q+'-++*)+*--*!(*!-+++(,++* ! +('(?+! Q+'-++*!! *-!''!()(,++* +*)! Q+('(,++-'*'()++!(-+--*.+++(++-! -- +(!+.!! ! Q'")"+."!!)*':42?*!'! Q+('

• R!"#* +'+*)*(,++* )'*.-'+42*:++'

.+*)'*.-'+)*+* :*

• A4

"0/"0 0"#

• !1"/,B

/91-,!&##) ()* ()+

• "/,B"0#C

D<"# /0 " "#"0 D<"#<B " "/,B #</#"#<" ,#(= # #-E"0

• E0

0-! $-+ :+-)+! ()*+'42 *

333< 333< 333<

• !$-+

:+()*+'-'42*

B===< ;444< 222<

,/$+ :+(!"+'-'42 *

222< 333< 333<

,,$+ (:+-)+! ()*+ '-'42*

333< 333< 333<

• ))() **)**)*! (!*"+()

+* $&* ''(!! !'*'+"(-'(!)+!++(*+,+') "+'!"#$%&+**'! '!(+(!'*-+(-' .'+))+!')+(!'*- "!!'Q'(!++(*+,+' +((*-+(* (!)!!'+'* !-!(++ *!!)*))( !!!+)))( !! +( 7(*+ +(!

• -

• 0(12345
• !"#*
• +'(+
• 5)@

!0 ,J!!"!+*

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

• S2345!"#$%&

• 0(12345
• !"#*
• +'(+
• @)@

!0 ,J!!"!+*